Translating MSC Therapy in the Age of Obesity

Mesenchymal stromal cell (MSC) therapy has seen increased attention as a possible option to treat a number of inflammatory conditions including COVID-19 acute respiratory distress syndrome (ARDS). As rates of obesity and metabolic disease continue to rise worldwide, increasing proportions of patient...

詳細記述

書誌詳細

出版年:	Frontiers in Immunology
主要な著者:	Lauren Boland, Laura Melanie Bitterlich, Andrew E. Hogan, James A. Ankrum, Karen English
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2022-07-01
主題:	mesenchymal stromal cells (MSCs) disease microenvironment obesity immunomodulation metabolic disease
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.943333/full